Cargando…

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs

INTRODUCTION: Once-weekly semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue administered at a 1.0 or 0.5 mg dose. As head-to-head trials assessing once-weekly semaglutide as an add-on to 1–2 oral anti-diabetic drugs (OADs) vs other GLP-1 receptor agonists (GLP-1 RAs) are limited, a netwo...

Descripción completa

Detalles Bibliográficos
Autores principales: Witkowski, Michal, Wilkinson, Lars, Webb, Neil, Weids, Alan, Glah, Divina, Vrazic, Hrvoje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984927/
https://www.ncbi.nlm.nih.gov/pubmed/29675798
http://dx.doi.org/10.1007/s13300-018-0424-2
_version_ 1783328681148547072
author Witkowski, Michal
Wilkinson, Lars
Webb, Neil
Weids, Alan
Glah, Divina
Vrazic, Hrvoje
author_facet Witkowski, Michal
Wilkinson, Lars
Webb, Neil
Weids, Alan
Glah, Divina
Vrazic, Hrvoje
author_sort Witkowski, Michal
collection PubMed
description INTRODUCTION: Once-weekly semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue administered at a 1.0 or 0.5 mg dose. As head-to-head trials assessing once-weekly semaglutide as an add-on to 1–2 oral anti-diabetic drugs (OADs) vs other GLP-1 receptor agonists (GLP-1 RAs) are limited, a network meta-analysis (NMA) was performed. The objective was to assess the relative efficacy and safety of once-weekly semaglutide vs GLP-1 RAs in patients with type 2 diabetes (T2D) inadequately controlled on 1–2 OADs. METHODS: A systematic literature review (SLR) was conducted in order to identify trials of GLP-1 RAs in patients inadequately controlled on 1–2 OADs. Data at 24 ± 4 weeks were extracted for efficacy and safety outcomes (feasible for analysis in a NMA), which included the key outcomes of change from baseline in glycated hemoglobin (HbA(1c)), systolic blood pressure (SBP), and weight, as well as discontinuation due to adverse events (AEs). Data were synthesized using a NMA and a Bayesian framework. RESULTS: In total, 26 studies were included across the base case analyses. Once-weekly semaglutide 1.0 mg was associated with significantly greater reductions in HbA(1c) and weight vs all GLP-1 RA comparators. Once-weekly semaglutide 0.5 mg also achieved significantly greater reductions in HbA(1c) and weight compared with the majority of other GLP-1 RAs. Both doses of once-weekly semaglutide were associated with similar odds of discontinuation due to AEs compared with other GLP-1 RAs. CONCLUSION: Overall, once-weekly semaglutide 1.0 mg as an add-on to 1–2 OADs is the most efficacious GLP-1 RA in terms of the reduction of HbA(1c) and weight from baseline after 6 months of treatment. In addition, the analysis suggests that once-weekly semaglutide is well tolerated and not associated with an increase in discontinuations due to AEs compared with other GLP-1 RAs. FUNDING: Novo Nordisk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-018-0424-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5984927
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-59849272018-06-13 A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs Witkowski, Michal Wilkinson, Lars Webb, Neil Weids, Alan Glah, Divina Vrazic, Hrvoje Diabetes Ther Original Research INTRODUCTION: Once-weekly semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue administered at a 1.0 or 0.5 mg dose. As head-to-head trials assessing once-weekly semaglutide as an add-on to 1–2 oral anti-diabetic drugs (OADs) vs other GLP-1 receptor agonists (GLP-1 RAs) are limited, a network meta-analysis (NMA) was performed. The objective was to assess the relative efficacy and safety of once-weekly semaglutide vs GLP-1 RAs in patients with type 2 diabetes (T2D) inadequately controlled on 1–2 OADs. METHODS: A systematic literature review (SLR) was conducted in order to identify trials of GLP-1 RAs in patients inadequately controlled on 1–2 OADs. Data at 24 ± 4 weeks were extracted for efficacy and safety outcomes (feasible for analysis in a NMA), which included the key outcomes of change from baseline in glycated hemoglobin (HbA(1c)), systolic blood pressure (SBP), and weight, as well as discontinuation due to adverse events (AEs). Data were synthesized using a NMA and a Bayesian framework. RESULTS: In total, 26 studies were included across the base case analyses. Once-weekly semaglutide 1.0 mg was associated with significantly greater reductions in HbA(1c) and weight vs all GLP-1 RA comparators. Once-weekly semaglutide 0.5 mg also achieved significantly greater reductions in HbA(1c) and weight compared with the majority of other GLP-1 RAs. Both doses of once-weekly semaglutide were associated with similar odds of discontinuation due to AEs compared with other GLP-1 RAs. CONCLUSION: Overall, once-weekly semaglutide 1.0 mg as an add-on to 1–2 OADs is the most efficacious GLP-1 RA in terms of the reduction of HbA(1c) and weight from baseline after 6 months of treatment. In addition, the analysis suggests that once-weekly semaglutide is well tolerated and not associated with an increase in discontinuations due to AEs compared with other GLP-1 RAs. FUNDING: Novo Nordisk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-018-0424-2) contains supplementary material, which is available to authorized users. Springer Healthcare 2018-04-19 2018-06 /pmc/articles/PMC5984927/ /pubmed/29675798 http://dx.doi.org/10.1007/s13300-018-0424-2 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Witkowski, Michal
Wilkinson, Lars
Webb, Neil
Weids, Alan
Glah, Divina
Vrazic, Hrvoje
A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs
title A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs
title_full A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs
title_fullStr A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs
title_full_unstemmed A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs
title_short A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs
title_sort systematic literature review and network meta-analysis comparing once-weekly semaglutide with other glp-1 receptor agonists in patients with type 2 diabetes previously receiving 1–2 oral anti-diabetic drugs
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984927/
https://www.ncbi.nlm.nih.gov/pubmed/29675798
http://dx.doi.org/10.1007/s13300-018-0424-2
work_keys_str_mv AT witkowskimichal asystematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs
AT wilkinsonlars asystematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs
AT webbneil asystematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs
AT weidsalan asystematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs
AT glahdivina asystematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs
AT vrazichrvoje asystematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs
AT witkowskimichal systematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs
AT wilkinsonlars systematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs
AT webbneil systematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs
AT weidsalan systematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs
AT glahdivina systematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs
AT vrazichrvoje systematicliteraturereviewandnetworkmetaanalysiscomparingonceweeklysemaglutidewithotherglp1receptoragonistsinpatientswithtype2diabetespreviouslyreceiving12oralantidiabeticdrugs